IL-17 Blockade in Psoriasis.
Cell
; 167(7): 1669, 2016 Dec 15.
Article
em En
| MEDLINE
| ID: mdl-27984714
IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Interleucina-17
/
Anticorpos Monoclonais Humanizados
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article